Dialysis patients and cardiovascular problems: Can technology help solve the complex equation?

Blood Purification

Volumn 24, Issue 1, 2006, Pages 39-45

  Ronco, Claudio ^a   Bowry, Sudhi ^b   Tetta, Ciro ^b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

Cardiovascular complications; Dialysis machine; Online hemodiafiltration

Indexed keywords

BIOMATERIAL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTAMINATION; DIABETES MELLITUS; DIALYSIS; HEART DISEASE; HEART PROTECTION; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY FAILURE; MEDICAL TECHNOLOGY; MONITORING; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

AGE FACTORS; CARDIOVASCULAR DISEASES; DEATH; DIABETES MELLITUS; HUMANS; KIDNEY FAILURE, CHRONIC; PATIENT CARE; RENAL DIALYSIS; RISK FACTORS; SEX FACTORS;

EID: 29244474088     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089435     Document Type: Review

References (61)

1. Go AS, Chertow GM, Fan D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
2. Culleton BF, Larson MG, Wilson PW, et al: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-2219.
3. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States; the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:3270-3277.
4. Foley RN: Cardiac disease in chronic uremia: can it explain the reverse epidemiology of hypertension and survival in dialysis patients? Semin Dial 2004;17:275-278.
5. Barret BJ: Reducing the burden of cardiovascular disease in patients on dialysis. Dial Transplant 2002;31:155-163.
6. Culleton BF, Hemmelgram B: Inadequate treatment of cardiovascular disease and cardiovascular disease risk factors in dialysis patients. Semin Dial 2004;17:342-345.
7. Port FK, Eknoyan G: The Dialysis Outcomes and Practice Patterns Study (DOPPS) and the Kidney Disease Outcomes Quality Initiative (K/DOQI): a cooperative initiative to improve outcomes for hemodialysis patients worldwide. Am J Kidney Dis 2004;44(suppl 3):1-6.
8. Sarnak MJ, Coronado BE, Greene T, et al: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002;57:327-335.
9. McMahon LP: Hemodynamic cardiovascular risk factors in chronic kidney disease: what are the effects of intervention? Semin Dial 2003;16:128-139.
10. Kalantar-Zadeh K, Block G, Humphreys MH, et al: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis. Kidney Int 2003;63:793-808.
11. Busch M, Franke S, Müller A, et al: Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004;66:338-347.
12. Uhlig K, Levey AS, Sarnak MJ: Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 2003;16:118-127.
13. Zoccali C, Mallamaci F, Tripepi G: Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003;63(suppl 85):S105-S110.
14. Levin A: Cardiac disease in chronic kidney disease: current understandings and opportunities for change. Blood Purif 2004;22:21-27.
15. Sarnak MJ: Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003;41:S11-S17.
16. Krane V, Wanner C: Cardiovascular disease and predisposing factors in chronic renal failure. J Clin Basic Cardiol 2001;4:97-100.
17. Coresh J, Astor B, Sarnak MJ: Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2004;13:73-81.
18. Ritz E: Atherosclerosis in dialyzed patients. Blood Purif 2004;22:28-37.
19. Stenvinkel P: Inflammation in end-stage renal disease - A fire that burns within. Contrib Nephrol 2005;149:185-199.
20. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
21. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-114.
22. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004;19:1154-1160.
23. Wratten ML, Galaris D, Tetta C, Sevanian A: Evolution of oxidative stress and inflammation during hemodialysis and their contribution to cardiovascular disease. Antioxid Redox Signal 2003;4:935-944.
24. Kramer H, Toto R, Peshock R, Cooper R, Victor R: Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2004;16:507-513.
25. Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-2219.
26. Jungers P, Massy ZA, Khoa TN, Labrunie M, Lacour B, Descamps-Latscha B, Man NK: Incidence and risk factors of atherosclerotic accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997;12:2597-2607.
27. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000;35:S117-S131.
28. Harjai KJ: Potentially new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein (a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999;131:376-386.
29. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O: Elevated serum levels of soluble adhesion molecules predict death in predialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000;15:1624-1630.
30. Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin N: Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001;60:333-340.
31. Bammens B, Evenepoel P, Verbeke K, et al: Protein-bound solutes: explaining the dissociation between urea reduction ratio and patient outcome? J Am Soc Nephrol 2003;14:911.
32. Jolivot A, Combarnous F, Geleen G, et al: Leptin kinetics and clearance during maintenance hemodialysis: effect of high-flux membranes. Nephrol Dial Transplant 2003;18(suppl 4):M617.
33. Wanner C, Bahner U, Mattern R, et al: Effect of dialysis flux and membrane material on dyslipidemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19:2570-2575.
34. Bowry SK: Dialysis membranes today. Int J Art Organs 2002;25:447-460.
35. Ronco C, Bowry S: Nanoscale modulation of the pore dimensions, size distribution and structure of a new polysulfone-based high-flux dialysis membrane. Int J Artif Organs 2001;24:726-735.
36. Ronco C, Bowry SK, Brendolan A, Crepaldi C, Soffiati G, Fortunato A, Bordoni V, Granziero A, Torsello G, La Greca G: Hemodialyzer: from macro-design to membrane nanostructure; the case of the FX-class of hemodialyzers. Kidney Int 2002;80(suppl):126-142.
37. Ayli D, Ayli M, Yuksei C, et al: The effect of high-flux hemodialysis on renal anemia. J Nephrol 2004;17:701-706.
38. Cappelli G, Tetta C, Canaud B: Is biofilm a cause of silent chronic inflammation in haemodialysis patients? A fascinating working hypothesis. Nephrol Dial Transplant 2005;20:266-270.
39. Weber V, Linsberger I, Rossmanith E, et al: Pyrogen transfer across high- and low-flux hemodialysis membranes. Artif Organs 2004;28:210-217.
40. Schindler R, Christ-Kohlrausch F, Frei U, Shaldon S: Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens. Clin Nephrol 2003;59:447-454.
41. Reznikov LL, Waksman J, Azam T, et al: Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004;61:324-336.
42. Hsu PY, Lin CL, Yu CC, et al: Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - A prospective cross-over study. J Nephrol 2004;17:693-700.
43. European Best Practice Guidelines for Haemodialysis (part 1): produced by the EBPG expert group on haemodialysis. Nephrol Dial Transplant 2002;17(suppl):7.
44. Bammens B, Evenepoel P, Verbeke K, et al: Removal of protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004;44:278-285.
45. Ahrenholz PG, Winkler RE, Bowry SK, et al: Dialysis membrane-dependent removal of middle molecules during hemodiafiltration: the β2-microglobulin/ albumin relationship. Clin Nephrol 2004;62:21-28.
46. Bonomini M, Ballone E, Di Stante S, et al: Removal of uraemic plasma factor(s) using different dialysis modalities reduces phosphatidylserine exposure in red blood cells. Nephrol Dial Transplant 2004;19:68-74.
47. Locatelli F, Buoncristiani U, Canaud B, et al: Haemodialysis with on-line monitoring equipment: tools or toys? Nephrol Dial Transplant 2005;20:22-33.
48. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003;14:3251-3263.
49. Di Fillipo S, Manzoni C, Andrulli S, et al: How to determine ionic dialysance for the online assessment of delivered dialysis dose. Kidney Int 2001;59:774-782.
50. Donauer J, Böhler J: Rationale for the use of blood volume and temperature control devices during hemodialysis. Kidney Blood Press Res 2003;26:82-89.
51. Boer W, Claus M, Cremaschi L, et al: Less intradialytic complications with blood volume control. Nephrol Dial Transplant 2002;17(suppl 1):127-128.
52. Maggiore Q, Pizzarelli F, Santoro A, et al: The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial. Am J Kidney Dis 2002;40:280-290.
53. Passlick-Deetjen J, Pohlmeier R: On-line hemodiafiltration. Gold standard or top therapy. Contrib Nephrol 2002;137:201-211.
54. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillispie BW, Depner T, Klassen P, Port FK: Patients receiving hemodiafiltration of hemofiltration have lower mortality risk than patients receiving hemodialysis without replacement fluid (HD) in Europe: The Dialysis Outcomes and Practice Patterns Study (DOPPS) (abstract). J Am Soc Nephrol 2003; 14:31A.
55. Steil H, Amato C, Carioni C, Kirchgessner J, Marcelli D, Mitteregger A, Moscardo V, Orlandini G, Gatti E: EuCliD - A medical registry. Methods Inf Med 2004;43:83-88.
56. Jirka T, Cesare S, Di Benedetto A, Perera Chang M, Ponce P, Richards N: The impact of on-line haemodiafiltration (HDF) on patient survival: results from a large network database. Nephrol Dial Transplant 2005;20:v18-v19.
57. Vaslaki LR, Berta K, Major L, Weber V, Weber C, Wojke R, Passlick-Deetjen J, Falkenhagen D: On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: results from a multicenter crossover study. Artif Organs 2005;29:406-412.
58. Pedrini LA, De Cristofaro VA: On-line mixed hemodiafiltration with a feedback for ultrafiltration control: effect on middle-molecule removal. Kidney Int 2003;4:1505-1513.
59. Man NK: Controversies and issues in hemodiafiltration therapy. Blood Purif 2004;22(suppl 2):2-7.
60. www.anaes.fr
61. Bowry SK, Kuchinke-Kiehn U, Ronco C: The cardiovascular burden of the dialysis patient: the impact of dialysis technology; in Ronco C, Brendolan A, Levin NW (eds): Cardiovascular Disorders in Hemodialysis. Contrib Nephrol. Basel, Karger, 2005, vol 149, pp 230-239.